Application of Deep Learning to Reduce the Rate of Malignancy Among BI-RADS 4A Breast Lesions Based on Ultrasonography.

Journal: Ultrasound in medicine & biology
Published Date:

Abstract

The aim of the work described here was to develop an ultrasound (US) image-based deep learning model to reduce the rate of malignancy among breast lesions diagnosed as category 4A of the Breast Imaging-Reporting and Data System (BI-RADS) during the pre-operative US examination. A total of 479 breast lesions diagnosed as BI-RADS 4A in pre-operative US examination were enrolled. There were 362 benign lesions and 117 malignant lesions confirmed by postoperative pathology with a malignancy rate of 24.4%. US images were collected from the database server. They were then randomly divided into training and testing cohorts at a ratio of 4:1. To correctly classify malignant and benign tumors diagnosed as BI-RADS 4A in US, four deep learning models, including MobileNet, DenseNet121, Xception and Inception V3, were developed. The performance of deep learning models was compared using the area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Meanwhile, the robustness of the models was evaluated by five-fold cross-validation. Among the four models, the MobileNet model turned to be the optimal model with the best performance in classifying benign and malignant lesions among BI-RADS 4A breast lesions. The AUROC, accuracy, sensitivity, specificity, PPV and NPV of the optimal model in the testing cohort were 0.897, 0.913, 0.926, 0.899, 0.958 and 0.784, respectively. About 14.4% of patients were expected to be upgraded to BI-RADS 4B in US with the assistance of the MobileNet model. The deep learning model MobileNet can help to reduce the rate of malignancy among BI-RADS 4A breast lesions in pre-operative US examinations, which is valuable to clinicians in tailoring treatment for suspicious breast lesions identified on US.

Authors

  • Zhijin Zhao
    School of Communication Engineering, Hangzhou Dianzi University, Hangzhou, China.
  • Size Hou
    Department of Applied Mathematics, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.
  • Shuang Li
    Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
  • Danli Sheng
    Department of Medical Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Qi Liu
    National Institute of Traditional Chinese Medicine Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Cai Chang
    Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Jiangang Chen
  • Jiawei Li
    School of Chemistry & Chemical Engineering, College of Guangling, Yangzhou University Yangzhou 225002 PR China zhuxiashi@sina.com.